Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 1:23 PM ET

Biotechnology

Company Overview of Epizyme, Inc.

Company Overview

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase II clinical trial of tazemetostat (EPZ-6438), an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and INI1-deficient solid tumors; and two Phase I clinical trials of pinometostat (EPZ-5676), an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with geneti...

400 Technology Square

4th Floor

Cambridge, MA 02139

United States

Founded in 2007

86 Employees

Phone:

617-229-5872

Fax:

617-349-0707

Key Executives for Epizyme, Inc.

Chief Scientific Officer and President of Research
Age: 58
Total Annual Compensation: $531.7K
Chief Medical Officer
Age: 53
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.

Epizyme, Inc. Key Developments

Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA

Epizyme, Inc. announced that the United States Food and Drug Administration (FDA) has granted orphan drug status to the company’s first-in-class EZH2 inhibitor, tazemetostat, for the treatment of malignant rhabdoid tumors (MRTs). In December 2015, the company initiated a phase 2 study in adults and a phase 1 study in children with genetically defined tumors, including MRTs. Tazemetostat is also being investigated in an ongoing five-arm phase 2 study in patients with non-Hodgkin lymphoma. Orphan drug designation provides the sponsor of the drug with eligibility for various development incentives, including tax credits for qualified clinical testing and marketing exclusivity for a period of seven years. Therapies with orphan drug status are also not subject to a prescription drug user fee for the orphan indication. Currently, treatment of MRT consists of surgery, chemotherapy and radiation therapy, which are associated with limited efficacy and significant treatment-related morbidity. MRT is a tumor defined by loss of INI1 protein as measured by immunohistochemistry. Other rhabdoid tumors, such as MRT of ovary, are characterized by loss of the protein SMARCA4 and have shown sensitivity to tazemetostat in preclinical models and in the phase 1 study. The orphan drug designation applies to both INI1-negative MRT as well as SMARCA4-negative MRT of ovary. The ongoing phase 2 adult and phase 1 pediatric studies in patients with genetically-defined solid tumors include patients with rhabdoid tumors, other INI1-negative tumors, and synovial sarcoma. Interim data from Epizyme’s registration-supporting phase 2 clinical study of tazemetostat in adult patients with genetically defined solid tumors, including MRT, other INI1-negative tumors and synovial sarcoma, are anticipated to be presented at a medical conference in late 2016.

Epizyme, Inc. Presents at Canaccord Genuity Rare Disease and BioPharma 1x1 Day, Feb-02-2016

Epizyme, Inc. Presents at Canaccord Genuity Rare Disease and BioPharma 1x1 Day, Feb-02-2016 . Venue: Omni Berkshire Place, New York, New York, United States.

Epizyme, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:05 AM

Epizyme, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:05 AM. Venue: The Waldorf Astoria, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Diagnostic Biochips, Inc. United States
Chaperone Technologies, Inc. United States
Accera, Inc. United States
Mira Dx, Inc. United States
Enzo Life Sciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Epizyme, Inc., please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.